A statistically clear difference still requires its size and time window.
A placebo-controlled trial in older patients with zoster-related pain reported modest pain-score differences on selected posttreatment days after intramuscular diazepam. A later sleep-quality measure also favored the intervention.
Seventy-eight participants were studied. Between-group pain-score differences were 0.62 on posttreatment day three and 0.66 on day four; a sleep-questionnaire difference was reported on day seven. These modest, time-specific findings are more informative than a general claim of effective pain management. They should remain separate from long-term postherpetic neuralgia, functional recovery and the patient’s tolerance of sedation.
The study involved concurrent clinical treatment and short follow-up. Improvement in pain ratings is not proof of antiviral activity, long-term prevention of neuralgia or an absence of benzodiazepine adverse effects. Selected significant days do not establish a uniform benefit throughout follow-up.
Report the measured difference and assessment day. The trial cannot establish that diazepam resolved an individual’s underlying disease or that improved sleep proves direct analgesia. Case review should distinguish symptom relief, sedation, recall and the other treatments received.
Source: PMC11134619, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Diazepam Worsened Activity in Some Immature Brain Slices but Improved Older Slices.